|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||177.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
More than 35 presentations and sessions showcase Shire`s gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology ...
All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.